Dravet syndrome
Neurology · 2020–2026
4decisions
3medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cannabidiol Severe myoclonic epilepsy in infancy (Dravet syndrome) — treatment of generalised tonic-clonic seizures or generalised clonic seizures that are not adequately… | Mar 2026 | Recommended with restriction | no section in document |
| fenfluramine Treatment of seizures associated with Dravet Syndrome in patients not adequately controlled despite treatment with at least 2 other antiepileptic drugs. | Nov 2024 | Recommended with restriction | input received Epilepsy Action Australia · Epilepsy Society |
| cannabidiol Adjunctive therapy to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), also known as severe myoclonic epilepsy in infancy… | Jul 2020 | Recommended with restriction | input received Epilepsy Society · Epilepsy Foundation |
| stiripentol Adjunctive therapy for severe myoclonic epilepsy in infancy (SMEI, also known as Dravet syndrome) with primary generalised clonic and tonic-clonic seizures in… | Mar 2020 | Recommended with restriction | none received |
Who spoke
Epilepsy Society · Epilepsy Foundation · Epilepsy Action Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.